Erlotinib is an ATP-competitive tyrosine kinase inhibitor specific to EGFR, which is approved by the Food and Drug Administration for targeting NSCLC (Kosaka et al. 2011). This evidence concerns the gene EGFR and non-small cell lung carcinoma.